Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellentra VCBM in ACDF Outcomes Study
NCT02182843Completed
- Sponsor
- Zimmer Biomet
- Start
- Mar 2014
- Primary completion
- Jan 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Cellentra Viable Cell Bone Matrix in cervical degenerative disc disease (CDDD), sponsored by Zimmer Biomet. Primary endpoint: Neck Disability Index at 12 months. Started Mar 2014; status: completed.
02
Drugs
Cellentra Viable Cell Bone Matrix
03
Conditions
cervical degenerative disc disease (CDDD)
Beyond the preview
Go deeper on NCT02182843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182843.